ReSynapse Therapeutics

𝗥𝗲𝗦𝘆𝗻𝗮𝗽𝘀𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀: 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗡𝗲𝘂𝗿𝗼𝗽𝘀𝘆𝗰𝗵𝗶𝗮𝘁𝗿𝘆 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗠𝘂𝗹𝘁𝗶-𝗧𝗮𝗿𝗴𝗲𝘁 𝗗𝗿𝘂𝗴 𝗗𝗲𝘀𝗶𝗴𝗻 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 𝗳𝗼𝗿 𝗦𝗲𝗿𝗼𝘁𝗼𝗻𝗶𝗻 𝗠𝗼𝗱𝘂𝗹𝗮𝘁𝗶𝗼𝗻 We're developing multi-target compounds for serotonin modulation to create fast-acting, long-lasting treatments for depression. Our approach: • Targets specific multi-CNS receptors simultaneously • Aims to overcome limitations of SSRIs and psychedelic-derived treatments • Utilizes advanced computational chemistry drug design platform Recent achievements: • Non-dilutive grant awarded for our novel "recipe" platform • Positive KOL evaluation of feasibility and validation Seeking seed funding for POC development and strategic partnerships to advance our mission. ReSynapse Therapeutics is developing the first systematic multi-target platform for precision neuropsychiatry, addressing the treatment-resistant depression crisis where current therapies fail 83.3% of patients. Using advanced computational chemistry, the company designs novel drugs that target specific receptor combinations with precise modulation modes, like programming an electronic key code, aiming to deliver a 1-2 week onset versus the 4-6 weeks required by traditional antidepressants. Led by serial entrepreneurs with $7M in prior exits and a Skolnik Prize-winning computational chemistry leader. The platform approach creates a scalable moat, positioning between failed single-target drugs and risky psychedelics to capture the 2.8 million Americans and 11 million Europeans suffering from treatment-resistant depression, with only 16.7% remission rates under current care.